Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2009

ProMetic to Provide Halozyme with Synthetic Ligand Affinity Adsorbent

  • Halozyme Therapeutics is employing ProMetic Life Sciences to supply a synthetic ligand affinity adsorbent. The agreement is for an initial five-year term with the opportunity for extension.

    The synthetic ligand adsorbent to be provided under the supply arrangement is used by Halozyme in the manufacture of its FDA-approved rHuPH20 product, a recombinant version of human hyaluronidase enzyme. ProMetic's synthetic ligand adsorbent has been used by Halozyme throughout the development of rHuPH20.

    Hyaluronidase temporarily degrades hyaluronan, a space-filling, gel-like substance that is an important structural component of tissues throughout the body, such as skin and cartilage. The enzyme is used to facilitate the penetration and diffusion of drugs and fluids that are injected under the skin or in the muscle.

    The product received FDA sanction in January 2006 for use as an adjuvant agent to increase the absorption and dispersion of other injected drugs.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »